Cancer diagnostic company Veracyte has agreed to acquire C2i Genomics, a minimal residual disease detection company, for $70 million. San Francisco, California-based Veracyte was advised by Fenwick & West corporate partners Doug Cogen, Ran Ben-Tzur and Einat Meisel. Counsel information for C2i Genomics, which is based in Haifa, Israel, was not immediately available.
Biotech & Pharmaceuticals
January 09, 2024, 10:43 AM